Top

Published in:

01-08-2016 | Letter to the editor

Re: “Prediction of skeletal-related events in patients with non-small cell lung cancer”—use of Spine Instability Neoplastic Score (SINS)

Authors: Estanislao Arana, Francisco M. Kovacs, Ana Royuela, Beatriz Asenjo, Úrsula Pérez-Ramírez, Javier Zamora, for the Spanish Back Pain Research Network Task Force for the improvement of inter-disciplinary management of spinal metastasis

Published in: Supportive Care in Cancer | Issue 8/2016

Excerpt

We congratulate Dr. Aiba et al. on their paper, in which the Spinal Instability Neoplastic Score (SINS) was used to assess skeletal-related events (SRE) in patients with non-small cell lung cancer (NSCLC) [1]. …

Aiba H, Kimura T, Yamagami T, Watanabe N, Sakurai H, Kimura H et al (2016) Prediction of skeletal-related events in patients with non-small cell lung cancer. Support Care Cancer. doi:10.1007/s00520-016-3167-5 PubMed

Arana E, Kovacs FM, Royuela A, Asenjo B, Pérez-Ramírez Ú, Zamora J (2015) Spine Instability Neoplastic Score: agreement across different medical and surgical specialties. Spine J. doi:10.1016/j.spinee.2015.10.006 PubMed

Arana E, Kovacs FM, Royuela A, Asenjo B, Pérez-Ramírez Ú, Zamora J (2015) Agreement in the assessment of metastatic spine disease using scoring systems. Radiother Oncol 115:135–40. doi:10.1016/j.radonc.2015.03.016 CrossRefPubMed

Title: Re: “Prediction of skeletal-related events in patients with non-small cell lung cancer”—use of Spine Instability Neoplastic Score (SINS)
Authors: Estanislao Arana
Francisco M. Kovacs
Ana Royuela
Beatriz Asenjo
Úrsula Pérez-Ramírez
Javier Zamora
for the Spanish Back Pain Research Network Task Force for the improvement of inter-disciplinary management of spinal metastasis
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 8/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3268-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2016

Early supportive medication use and end-of-life care among Medicare beneficiaries with advanced breast cancer

Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review

Patients’ understanding of treatment goals and disease course and their relationship with optimism, hope, and quality of life: a preliminary study among advanced breast cancer outpatients before receiving palliative treatment

Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study

Kinesiology taping as an adjunct for the management of symptoms in the continuum of cancer care?

Implementation of a mobile inpatient quality of life (QoL) assessment for oncology nursing

Keynote webinar | Spotlight on antibody–drug conjugates in cancer